ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis-Reference-Cited by-同舟云学术

ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis

Published:2017-09 Issue: Volume:28 Page:v627
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Clamp A.R.,McNeish I.,Dean A.,Gallardo D.,Weon-Kim J.,O'Donnell D.,Hook J.,Coyle C.,Blagden S.P.,Brenton J.,Naik R.,Perren T.,Sundar S.,Cook A.,James E.,Swart A.M.,Stenning S.,Kaplan R.,Ledermann J.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/suppl_5/mdx440.039/19941864/mdx440.039.pdf

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Annals of Oncology;2023-10

2. Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial;JCO Clinical Cancer Informatics;2023-04

3. Olaparib maintenance therapy after frontline chemotherapy in patients with BRCA-mutated ovarian cancer: real-world results in expanded access program;Meditsinskiy sovet = Medical Council;2022-06-18

4. Overview of Ovarian Cancer Chemotherapy;Advances in Diagnosis and Management of Ovarian Cancer;2022

5. Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment;Cancers;2021-12-12